Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia

The group of patients with refractory acute myeloid leukemia includes those patients who fail standard induction chemotherapy, who relapse within 6 months after first complete remission, and who have relapsed twice or more. The outcome of these patients is usually very poor, with only a small proportion who can be rescued by allogenic hematopoietic stem cell transplantation. The aim of this study is to evaluate the efficacy and feasibility of allogenic hematopoietic stem cell transplantation in patients with refractory acute myeloid leukemia.

Source: Clinical Lymphoma, Myeloma and Leukemia - December 5, 2018 Category: Hematology Authors: Rafiye Ciftciler, Haluk Demiroglu, Yahya Buyukas ık, Elifcan Aladag, Salih Aksu, Ibrahim C. Haznedaroglu, Nilgun Sayınalp, Osman Ozcebe, Umit Yavuz Malkan, Hakan Goker Tags: Original Study Source Type: research